Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.

Hypertens Res · 2020 · PMC7685977 · PMID 32616846

Europe PMC DOI

hedged sentence

0.0360

closest p · 0.7× alpha

0.0360

boldest claim

The sentences

a nonsignificant trendP = 0.036actually significant

Compared with the vehicle group, esaxerenone monotherapy showed a nonsignificant trend toward a decrease in MCP-1 excretion at 4 ( P = 0.036, n = 11) and 8 weeks ( P = 0.078, n = 11); however, there were no specific effects with olmesartan alone.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.